The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant tenosynovial giant ...

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...

Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several ...

It’s two months into the new year and many are continuing to pursue their fitness goals to improve their health and bulk-up ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update ...

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with ...